Copyright
©The Author(s) 2021.
World J Clin Oncol. Oct 24, 2021; 12(10): 845-867
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.845
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.845
Figure 1 Interleukin-6, interleukin-23 e transforming growth factor-β stimuli for interleukin-17A production and the role of Prostalglandins E2 in Th17 cells transdifferentiation into interleukin-17NEG FOXP3 cell.
TGF: Transforming growth factor; IL: Interleukin; PGE2: Prostalglandins E2.
Figure 2 Main protumor mechanisms related to the Th17 immune response profile.
STAT3: Signal transducer and activator of transcription 3; MMP2: Matrix metalloproteinases 2; VEGF: Vascular endothelial growth factor; PD-L1: Programmed death-ligand 1; PGE1: Prostalglandins E1; PGE2: Prostalglandins E2; TIM-3: T-cell immunoglobulin-3; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; AP-1: Activating protein-1.
- Citation: Marques HS, de Brito BB, da Silva FAF, Santos MLC, de Souza JCB, Correia TML, Lopes LW, Neres NSM, Dórea RSDM, Dantas ACS, Morbeck LLB, Lima IS, de Almeida AA, Dias MRJ, de Melo FF. Relationship between Th17 immune response and cancer. World J Clin Oncol 2021; 12(10): 845-867
- URL: https://www.wjgnet.com/2218-4333/full/v12/i10/845.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i10.845